BOULDER, Colo.–(BUSINESS WIRE)–Phase 2 data for CRS3123 to treat C. difficile infections (CDI) show high clinical cure rates and very low recurrence rates.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
COLORADO SPRINGS, Colo., May 26, 2022 /PRNewswire/ — Jeffery C. Platt, DDS, is being recognized by Continental Who’s Who as a Lifetime Achiever for his excellence in the Dental field and in acknowledgment of his […]
Researchers at the University of Colorado Anschutz and the University of Colorado Boulder have developed a miniature microscope that allows scientists to observe and activate individual brain cells during natural movement, an advance that could […]
InnerTrek now accepting applications for Colorado’s first training program, which is available virtually to students worldwide BOULDER, Colo., Dec. 3, 2024 /PRNewswire/ — InnerTrek, an Oregon-based psilocybin facilitator training program, is now licensed by Colorado’s […]
Copyright © 2026 Biotech Networks
